Heart Study Articles & Analysis: Older
32 news found
Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of ...
Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a new study in the Journal of Cardiovascular Translational Research that examined pressure-volume profiles in heart failure patients using Daxor’s BVA-100 blood test to measure intravascular volume overload compared to a commercially available ...
(NASDAQ:IRTC), a leading cardiovascular diagnostics and digital healthcare solutions company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the results of four clinical studies presented at the American Heart Association’s (AHA) 2022 Scientific Sessions in Chicago, IL. ...
A sustained rapid heartbeat can also put stress on the heart and slow the movement of blood through the atria, increasing the risk of stroke, among other comorbidities2. ...
We are delighted to explore new indications and now start using PiCSO for inferior STEMI patients in the context of the PiCSO-AMI-V study,” says Prof. Carrié. The principal investigator of the study is Professor Adrian Banning, Oxford Heart Center, Oxford, UK. “We are pleased to be initiating the PiCSO-AMI-V ...
EchoPixel’s True3D software platform, a pre-operative planning technology that creates a hologram of the heart for study before an incision is ever made, has received PMDA Medical Device Registration and Approval in Japan. This first-of-its-kind software enables the entire heart surgical team to develop a precise personalized plan by ...
The results of the study show that Daxor’s BVA-100 provides unique and actionable data that is critical for addressing heart failure in patients. ...
The DSMB performed a risk-benefit assessment, indicated no significant safety concerns, and recommended that the study continue as designed. “It is promising that the most recent risk/benefit analysis of this substantial data pool conducted by the DSMB indicates that the CardiAMP Cell Therapy Heart Failure Trial continues to have the potential to meet its ...
Progress Update December 27th, 2021 Year End Summary 2021 was a great year of progress for Second Heart Assist, Inc. We completed a large series of large animals with long duration use at Texas Heart Institute with great success. We believe we are set now to begin a cardio-renal syndrome clinical study with 24 hours circulatory assist support ...
New Phase III study VICTOR will assess vericiguat efficacy and safety in patients who have not had a recent worsening heart failure event / VICTOR expands upon the Phase III VICTORIA study, providing further insight into the use of vericiguat in a broader range of patients with chronic heart failure with reduced ejection fraction ...
ByBayer AG
Patients eligible to undergo the cell therapy procedure receive cells delivered with a system that has been shown in published literature to present the lowest risk to patients for biotherapeutic delivery1 and to be three to six times more efficient at delivering cells to the heart muscle than other methods.2 This approach allows the patient to be discharged from the hospital the ...
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, today announces that it has received final approval from the Patient Protection Committee (CPP ...
ByCarmat
The implant was performed at UofL Health – Jewish Hospital by University of Louisville physicians within the framework of the U.S. Early Feasibility Study. CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to ...
ByCarmat
Alleviant Medical Inc., a privately-held medical device company, today announced one-month and three-month follow up data from the first in human clinical study (ALLEVIATE-HF-1) of its technology for the treatment of heart failure with preserved ejection fraction (HFpEF). ...
Coala Life today announced the results of the RedHeart Study where the Coala Heart Monitor (“Coala”) was used to evaluate 821 women with palpitation symptoms over 60 days. ...
Berlin, March 2021: With the first-in-man implantation of the Berlin Heart Venous Cannula at the LMU University Hospital Munich (Grosshadern), Germany, Berlin Heart offers patients with a failing Fontan circulation a unique chance to survive the waiting time for a donor heart. ...
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure (CHF) via Transcatheter Ventricular Restoration (TCVR), today announced that heart failure specialist Jerry Estep, MD, of the Cleveland Clinic has been appointed co-principal investigator of the pivotal ALIVE Trial studying LIVE Therapy using ...
Following a telemedicine-based prescription, a Coala Heart Monitor is shipped directly to the patients’ home, and patient education is provided. ...
NEWS PROVIDED BY Second Heart Assist, Inc. June 22nd, 2020 7:00am ET Salt Lake City, Utah, June 22nd, 2020 /PRDistribution/ — Second Heart Assist Inc., inventors of the first, true, aortic stent-based circulatory assist pump intended primarily for use in heart failure patients, announces the successful completion of a series of ...